SITC Immuno-Oncology Drug Development Summit

The SITC Immuno-Oncology Drug Development Summit will take place from Sept. 30–Oct. 1, 2024 in Boston at The Revere Hotel Boston Common. This summit will help educate and engage the entire immuno-oncology (IO) community on the next wave of IO therapeutics and ensure that active, innovative, new therapies are rapidly and appropriately moved into clinical testing. This program will be a key forum for continuing exploration and discussion of best practices for modern IO drug development, including study design, regulatory pathways and emerging technologies.

The Organizers of the event are:

• Amy McKee, Chief Medical Officer and Global Head, Oncology Center of Excellence at Parexel,
• Pedro J. Romero, Chief Medical and Scientific Officer at Novigenix,
• Luisa Salter-Cid, CEO of Pioneering Medicines, Flagship Pioneering,
• Jon M. Wigginton, President of Research and Development at Bright Peak Therapeutics,
• Alexandra Snyder, Executive Vice President, Head of R&D at Generate Biomedicines,

Ignacio Melero, Professor of Immunology, Co-director of the Immunology and Immunotherapy Service at the University Hospital of Navarra, will present his keynote on “Cancer Immunotherapy: Tomorrow’s Treatment Combinations Today”.

More information here.

Other posts featuring Society for Immunotherapy of Cancer.